NCT05842174 2026-04-16
TAQE
VA Office of Research and Development
Phase 1/2 Recruiting
Clinical Trials
24 trialsNCT01480154 2026-04-13
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05518110 2026-04-13
PaTcH
Cancer Trials Ireland
Phase 2 Terminated
NCT04841148 2026-04-09
PALAVY
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT04132505 2026-04-06
Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT05036226 2026-03-30
COAST
Medical University of South Carolina
Phase 1/2 Recruiting
NCT03598595 2026-02-04
Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT06408298 2026-02-04
HCQ in Resectable Localized Prostate Cancer
Dartmouth-Hitchcock Medical Center
Phase EARLY_PHASE1 Recruiting
NCT04201457 2026-02-03
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
Pediatric Brain Tumor Consortium
Phase 1/2 Active not recruiting
NCT04524702 2026-01-23
Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
Emory University
Phase 2 Completed
NCT06971744 2025-12-22
Autophagy Maintenance (AUTOMAIN)
Medical University of South Carolina
Phase 2 Recruiting
NCT05843188 2025-12-09
Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer
University Health Network, Toronto
Phase 2 Active not recruiting
NCT05576896 2025-10-20
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Northwestern University
Phase 2 Recruiting
NCT00977470 2025-10-15
Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT05221320 2025-09-25
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
BioMed Valley Discoveries, Inc
Phase 2 Terminated
NCT03037437 2025-09-04
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT04669197 2025-08-15
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer
HonorHealth Research Institute
Phase 2 Active not recruiting
NCT01506973 2025-07-25
A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
Phase 1/2 Completed
NCT03377179 2025-07-23
A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma
RedHill Biopharma Limited
Phase 2 Completed
NCT03032406 2025-07-22
CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer
Abramson Cancer Center at Penn Medicine
Phase 2 Active not recruiting
NCT07061717 2025-07-11
Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Not yet recruiting
NCT04464759 2025-07-08
LIMIT
Abramson Cancer Center at Penn Medicine
Phase 1/2 Recruiting
NCT04379492 2025-05-16
A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19
Memorial Sloan Kettering Cancer Center
Phase 2 Withdrawn
NCT06939582 2025-04-29
RIOM
West China Hospital
Phase 1/2 Recruiting